Abstract:Base editing shows promise for the correction of human mutations at a higher efficiency than other repair methods and is especially attractive for mutations in large genes that are not amenable to gene augmentation therapy. Here, we demonstrate a comprehensive workflow for in vitro screening of potential therapeutic base editing targets for the USH2A gene and empirically validate the efficiency of adenine and cytosine base editor/guide combinations for correcting 35 USH2A mutations. Editing efficiency and bystander edits are compared between different target templates (plasmids versus transgenes) and assays (Next generation sequencing versus Sanger), as well as comparisons between unbiased empirical results and computational predictions. Based on these observations, practical assay recommendations are discussed. Finally, a humanized knock-in mouse model was created with the best-performing target, the nonsense mutation c.11864G>A p.(Trp3955*). Split-intein AAV9 delivery of editing reagents resulted in the restoration of USH2A protein and a correction rate of 65+/-3% at the mutant base pair and of 52+/-3% excluding bystander amino acid changes. This efficiency compares favorably to a prior genome editing strategy tested in the retina that completed a clinical trial and demonstrates the effectiveness of this overall strategy to identify and test base editing reagents with the potential for human therapeutic applications.

Cytosine and Adenine Base Editing of the Brain, Liver, Retina, Heart and Skeletal Muscle of Mice Via Adeno-Associated Viruses

Efficient in Vivo Base Editing Via Single Adeno-Associated Viruses with Size-Optimized Genomes Encoding Compact Adenine Base Editors

Adenine Base Editing in vivo with a Single Adeno-Associated Virus Vector

Efficient prime editing in mouse brain, liver and heart with dual AAVs

Mitochondrial adenine base editing of mouse somatic tissues via adeno-associated viral delivery

Adenine base editor‐based correction of the cardiac pathogenic Lmna c.1621C > T mutation in murine hearts

Adenine transversion editors enable precise, efficient A•T-to-C•G base editing in mammalian cells and embryos

In vivo mitochondrial base editing via adeno-associated viral delivery to mouse post-mitotic tissue

Amelioration of an Inherited Metabolic Liver Disease through Creation of a De Novo Start Codon by Cytidine Base Editing.

Development Of Highly Efficient Dual-Aav Split Adenosine Base Editor For In Vivo Gene Therapy

Adenine Base Editing in an Adult Mouse Model of Tyrosinaemia

Precision genome editing using cytosine and adenine base editors in mammalian cells

An All-in-one AAV Vector for Cardiac-Specific Gene Silencing by an Adenine Base Editor

Therapeutic adenine base editing corrects nonsense mutation and improves visual function in a mouse model of Leber congenital amaurosis

Engineering a Precise Adenine Base Editor with Minimal Bystander Editing.

Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

Systematic empirical evaluation of individual base editing targets: validating therapeutic targets in USH2A and comparison of methods

In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease

Engineering precise adenine base editor with infinitesimal rates of bystander mutations and off-target editing

Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope